such as the role of adjuvants, which are ingredients to boost the body’s immune response. And the FDA proposed revising the current system for reporting side effects or adverse events related to ...

Nouryon has announced the launch of Adsee Flex 960 at the ISAA Symposium 2025 in Rio de Janeiro, Brazil, held from April 6-11, 2025. This latest innovation for crop protection is a patented technology ...

Department of Chemistry, State Key Laboratory of Molecular Engineering of Polymers, Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, College of Chemistry and Materials, Fudan ...

This meta-analysis evaluated the efficacy and safety of adjuvant immunotherapy in patients with completely resected NSCLC and wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma ...

Artificial intelligence (AI) can accurately suggest appropriate adjuvant treatment for patients with early breast cancer, according to research published in JCO Clinical Cancer Informatics.

Bayer – through its indirect subsidiary Monsanto – has filed its petition for a writ of certiorari with the U.S. Supreme Court in the Durnell case, just three business days after the Missouri Supreme ...

Today (April 5), the Breakthrough Prize Foundation announced the recipients of the 2025 Breakthrough Prizes. Dubbed the “Oscars of Science,” these prestigious awards celebrate groundbreaking ...

Data collected included age, sex, Breslow thickness (BT), ulceration status of the primary tumor, nodal metastasis, sentinel lymph node biopsy (SLNB), complete lymph node dissection (CLND), substage, ...

Adjuvant chemotherapy is chemotherapy that you receive after your primary treatment. Its goal is to lower the chance that the cancer returns and to destroy any cancer cells that remain after surgery.

Findings of the phase 2 INFINITY trial (NCT04817826) indicate that a chemotherapy-free regimen of tremelimumab (Imjudo) plus durvalumab (Imfinzi; T300/D) exhibited promising antitumor activity in ...

This study provides valuable insights into the efficacy and safety of pyrotinib as an extended adjuvant therapy following trastuzumab-based treatment in patients with high-risk HER2-positive breast ...

The study by Ma et al. provides fundamental findings and compelling evidence that Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A ...